Data-driven insights for disease research and drug discovery

Get Started
molecule background molecule background

Indication Selection Case Study

Download Case Study
molecule background molecule background

eGuide: A data-driven approach to indication selection

Download eGuide
molecule background molecule background
Enabling world leading pharma, biotech and academic institutions
Genmab
Janssen and Janssen Pharmaceutical Companies
Leiden Academic Centre for Drug Research
Astra Zeneca
Boehringer Ingelheim
Tufts University
Euretos
data-driven research

Ready-to-use AI capabilities for disease and drug researchers

We enable researchers from pharma, biotech and academia to generate data-driven disease insights in human disease biology. We provide a unique combination of predictive computational disease models and direct access to our AI-integrated knowledge base to evaluate predictions and findings. This empowers scientists to draw their own conclusions and take a data-driven approach to disease research and preclinical drug discovery.
Contact Us
x
Euretos
Disease Modelling

Predictive computational disease models

Euretos has created AI-driven computational disease models that have been tried and tested with many leading pharma and biotech companies. These disease models systematically evaluate gene-disease associations across the whole indication landscape to predict novel target-indication combinations.
Find out More
Euretos
Knowledge Base

The world's largest AI-integrated knowledge base

We use AI to recognise and connect relevant information from hundreds of biomolecular databases and millions of publications and patents.
Find out More

The cloud AI platform for target and disease research

Use the Euretos AI Platform to assess key target and disease aspects such as multi-omics interactions, gene expression in tissues, cell types and tumors, pathway interactions, regulatory and signalling responses, gene variants, clinical trials, target tractability and patents.

Find out More
Search - Optimised for disease and drug biology
Analytics - Systems biological multi-omics insights
Knowledge Graph - Biomolecular interaction analysis
Workflows - Target evaluation, Single-cell study viewer (and much more)
Enabling world leading pharma, biotech and academic institutions
Logo Johnson & Johnson-1
Logo Grunenthal-2
Logo Daiichi Sankyo-1
PivotSC-logo-RGB-01-1 (1)-1
Logo Sanofi
Logo EMC

Euretos Newsletter

Subscribe to our mailing list and receive our quarterly updates!

Read our Terms and Conditions

Sign up for our newsletter

Subscribe to our quarterly market update
Euretos Indication Expansion-2
Client review

Indication Selection

"“In this project we evaluated you against our internal investigations and the results of one other external provider. What really sets you apart is how you combine a fundamentally biological and data driven approach. The breadth of the indications you assess and the depth of your analysis sets you apart and is a clear value add to our internal capabilities.” "

Global Head Large European Pharma
Euretos Target discovery-2
Client review

Target Discovery

"“We worked with Euretos to leverage their AI capabilities with the aim of finding new targets in two different indications. It was a real pleasure to work with them and the whole process was characterized by transparency, their willingness to listen to our needs and suggestions, and swift responses and data delivery. In addition, we found their platform very useful for getting an overview of the different targets and for general inquiries.“"

Tau Benned-Jensen Senior Research Scientist, H. Lundbeck A/S
Target Evaluation
Client review

Target Evaluation

""We are fascinated by the suggested hypothesis. It was great that even very small expressional changes were captured and a hypothesis was generated. The interpretation was also convincing and consistent. Also the team is well engaged, and had a very good understanding in the background of the project and our research question""

Principal Scientist Large Japanese Pharma
Euretos AI platform on laptop
Client review

Euretos AI Platform

"I find the Euretos platform to be valuable in what it offers in terms of advanced AI capabilities and analytics of smart scouting and literature searches to probe relevant targets, indications, and therapeutics. The professional support and dedicated mentoring from experienced bioinformatics professionals that Euretos offers greatly enhances our ability to take advantage of all the capabilities of the platform, and extract meaningful insights for our day to day mission of bringing innovation into Teva."

Dr. Dana Bar-On Sr. Director, Head of Academic Affairs and Networks, Specialty R&D, Teva Pharmaceuticals
Euretos Target discovery-2
Client review

Target Discovery

"We have been working with Euretos for many years now. They provide us with unique tools that we use as an integral part of our target discovery and validation. Using the Euretos AI platform is a mandatory input to our target discovery meetings."

Director Target Discovery Large European Biotech
Euretos Indication Expansion-2
Client review

Indication Selection

"We find that the Euretos group was very easy to work and communicate with. The professional staff at Euretos did a great job extending their platform and capabilities to our advantage. Euretos helped us to extract meaningful information from a highly complex data domain, that we could build on internally."

Henriette Husum Bak-Jensen Project Manager, Projects & Portfolio department, H. Lundbeck A/S

Pharma & Biotech Services

We collaborate with the world’s leading pharma & biotech companies to lower the risks and time frames in drug discovery. We combine computational disease models that predict novel gene-disease associations with an AI integrated knowledge base that enables rapid evaluation by domain experts.

Target Discovery

Novel target predictions to improve preclinical pipeline performance in all therapeutic areas.

Indication Selection

Novel disease association predictions to expand indications of existing drugs.

Target Evaluation

Accelerate assessment of target candidates from in-house discovery and in-licensing

Transforming Disease and Drug Research

Get Started Free access for academic users!
Book a demo